Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:CDC27-C17orf53

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: CDC27-C17orf53
	FusionPDB ID: 14801
	FusionGDB2.0 ID: 14801
		Hgene	Tgene
	Gene symbol	CDC27	C17orf53
	Gene ID	996	78995
	Gene name	cell division cycle 27	homologous recombination factor with OB-fold
	Synonyms	ANAPC3\|APC3\|CDC27Hs\|D0S1430E\|D17S978E\|H-NUC\|HNUC\|NUC2	C17orf53\|MCM8IP
	Cytomap	17q21.32	17q21.31
	Type of gene	protein-coding	protein-coding
	Description	cell division cycle protein 27 homologD0S1430E, D17S978Eanaphase promoting complex subunit 3anaphase-promoting complex, protein 3cell division cycle 27 homolognuc2 homolog	uncharacterized protein C17orf53MCM8-9-Interacting Protein)homologous recombincation factor with OB-fold
	Modification date	20200313	20200313
	UniProtAcc	P30260 Main function of 5'-partner protein: FUNCTION: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. {ECO:0000269\|PubMed:18485873}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000446365, ENST00000066544, ENST00000527547, ENST00000531206, ENST00000528748,	ENST00000245382, ENST00000319977, ENST00000585683,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	12 X 8 X 10=960	2 X 2 X 2=8
	# samples	16	2
	** MAII score	log2(16/960*10)=-2.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(2/8*10)=1.32192809488736
Fusion gene context	PubMed: CDC27 [Title/Abstract] AND C17orf53 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: CDC27 [Title/Abstract] AND C17orf53 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CDC27(45219219)-C17orf53(42231924), # samples:2
Anticipated loss of major functional domain due to fusion event.	CDC27-C17orf53 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. CDC27-C17orf53 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	CDC27	GO:0070979	protein K11-linked ubiquitination	18485873

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:45219219/chr17:42231924)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across CDC27 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across C17orf53 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000066544	CDC27	chr17	45219219	-	ENST00000319977	C17orf53	chr17	42231924	+	2684	1645	94	2139	681
ENST00000066544	CDC27	chr17	45219219	-	ENST00000585683	C17orf53	chr17	42231924	+	2490	1645	94	2136	680
ENST00000066544	CDC27	chr17	45219219	-	ENST00000245382	C17orf53	chr17	42231924	+	2572	1645	94	1986	630
ENST00000531206	CDC27	chr17	45219219	-	ENST00000319977	C17orf53	chr17	42231924	+	2612	1573	4	2067	687
ENST00000531206	CDC27	chr17	45219219	-	ENST00000585683	C17orf53	chr17	42231924	+	2418	1573	4	2064	686
ENST00000531206	CDC27	chr17	45219219	-	ENST00000245382	C17orf53	chr17	42231924	+	2500	1573	4	1914	636
ENST00000527547	CDC27	chr17	45219219	-	ENST00000319977	C17orf53	chr17	42231924	+	2639	1600	52	2094	680
ENST00000527547	CDC27	chr17	45219219	-	ENST00000585683	C17orf53	chr17	42231924	+	2445	1600	52	2091	679
ENST00000527547	CDC27	chr17	45219219	-	ENST00000245382	C17orf53	chr17	42231924	+	2527	1600	52	1941	629

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000066544	ENST00000319977	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001300819	0.9986992
ENST00000066544	ENST00000585683	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001140754	0.9988593
ENST00000066544	ENST00000245382	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001570288	0.9984297
ENST00000531206	ENST00000319977	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001080695	0.99891937
ENST00000531206	ENST00000585683	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.000982807	0.99901724
ENST00000531206	ENST00000245382	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.00147377	0.9985262
ENST00000527547	ENST00000319977	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001264385	0.9987356
ENST00000527547	ENST00000585683	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.001254738	0.9987452
ENST00000527547	ENST00000245382	CDC27	chr17	45219219	-	C17orf53	chr17	42231924	+	0.00171154	0.99828845

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CDC27-C17orf53

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
CDC27	chr17	45219219	C17orf53	chr17	42231924	1573	522	QIGRAYFELSEYMQAALKQLPRNKVP
CDC27	chr17	45219219	C17orf53	chr17	42231924	1573	523	IGRAYFELSEYMQQAALKQLPRNKVP
CDC27	chr17	45219219	C17orf53	chr17	42231924	1600	515	QIGRAYFELSEYMQAALKQLPRNKVP
CDC27	chr17	45219219	C17orf53	chr17	42231924	1600	516	IGRAYFELSEYMQQAALKQLPRNKVP
CDC27	chr17	45219219	C17orf53	chr17	42231924	1645	516	QIGRAYFELSEYMQAALKQLPRNKVP
CDC27	chr17	45219219	C17orf53	chr17	42231924	1645	517	IGRAYFELSEYMQQAALKQLPRNKVP

Top

Potential FusionNeoAntigen Information of CDC27-C17orf53 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

CDC27-C17orf53_45219219_42231924.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:02	SEYMQQAA	0.9997	0.6862	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B45:01	SEYMQQAA	0.9995	0.874	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B48:01	MQAALKQL	0.9961	0.7113	12	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B47:01	SEYMQAAL	0.9959	0.5222	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:01	SEYMQAAL	0.9924	0.9067	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B41:01	SEYMQQAA	0.9753	0.9464	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:13	SEYMQAAL	0.8673	0.9333	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:01	SEYMQQAA	0.8634	0.7877	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B13:01	SEYMQQAAL	0.9949	0.9198	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B48:01	MQQAALKQL	0.9929	0.7683	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B45:01	FELSEYMQA	0.9901	0.8865	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B44:03	SEYMQQAAL	0.99	0.938	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:22	YMQAALKQL	0.9888	0.5846	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:60	YMQAALKQL	0.9859	0.5221	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B47:01	SEYMQQAAL	0.9818	0.6142	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:02	SEYMQQAAL	0.98	0.5641	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:04	YMQAALKQL	0.9787	0.7184	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:02	FELSEYMQA	0.978	0.6825	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:17	YMQAALKQL	0.9747	0.645	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:21	YMQAALKQL	0.9731	0.5851	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:27	YMQAALKQL	0.9642	0.5311	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:13	YMQAALKQL	0.9638	0.6167	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B14:02	SEYMQQAAL	0.9328	0.833	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B14:01	SEYMQQAAL	0.9328	0.833	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:22	ELSEYMQQA	0.9283	0.5579	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B45:01	SEYMQQAAL	0.9283	0.8715	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:01	SEYMQQAAL	0.914	0.9232	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:38	YMQAALKQL	0.9028	0.6264	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:19	YMQAALKQL	0.8548	0.5455	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:03	MQQAALKQL	0.8321	0.8986	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:13	MQQAALKQL	0.8305	0.9791	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:10	MQQAALKQL	0.77	0.7897	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B13:02	MQQAALKQL	0.7274	0.7015	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:13	SEYMQQAAL	0.6867	0.9426	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B41:01	FELSEYMQA	0.6835	0.9686	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B13:01	MQQAALKQL	0.6782	0.9896	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:01	SEYMQQAAL	0.6722	0.9374	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:01	FELSEYMQA	0.5703	0.7583	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:10	SEYMQQAAL	0.5133	0.6432	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B41:01	SEYMQQAAL	0.5047	0.8197	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:37	SEYMQQAAL	0.4626	0.7628	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:01	SEYMQQAAL	0.3851	0.759	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:03	SEYMQQAAL	0.3271	0.8073	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B13:01	YMQAALKQL	0.1206	0.9633	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B52:01	MQQAALKQL	0.1001	0.9794	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B52:01	SEYMQQAAL	0.0874	0.8932	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:01	FELSEYMQAA	0.8862	0.7925	6	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:01	FELSEYMQQA	0.8189	0.7803	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:67	FELSEYMQQA	0.7481	0.5754	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:24	FELSEYMQQA	0.7481	0.5754	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:30	FELSEYMQQA	0.7481	0.5754	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:22	FELSEYMQQA	0.7183	0.6342	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:13	FELSEYMQQA	0.5161	0.709	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B45:01	AYFELSEYMQA	0.9013	0.9124	4	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:06	SEYMQQAA	0.9999	0.5921	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:06	SEYMQAAL	0.9998	0.5309	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:08	SEYMQAAL	0.9732	0.7511	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:06	SEYMQQAAL	0.9993	0.5398	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:06	FELSEYMQA	0.9965	0.5346	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C03:07	YMQAALKQL	0.9901	0.9128	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:07	YMQAALKQL	0.9868	0.5182	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:05	YMQAALKQL	0.9813	0.5695	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:04	MQQAALKQL	0.9436	0.9398	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C01:17	YMQAALKQL	0.8993	0.9638	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B48:03	MQQAALKQL	0.8788	0.5513	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:05	MQQAALKQL	0.8209	0.6217	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:08	SEYMQQAAL	0.7627	0.7554	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:08	MQQAALKQL	0.7085	0.9499	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:09	SEYMQQAAL	0.6909	0.7773	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B14:03	SEYMQQAAL	0.6712	0.8295	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C01:30	YMQAALKQL	0.6629	0.9685	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:05	SEYMQQAAL	0.655	0.9253	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:12	SEYMQQAAL	0.6305	0.9443	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C07:29	YMQAALKQL	0.6077	0.9047	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:06	FELSEYMQQA	0.9818	0.5603	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:01	FELSEYMQQA	0.7481	0.5754	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:04	SEYMQAAL	0.9997	0.7204	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:05	SEYMQAAL	0.9924	0.9067	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:08	SEYMQAAL	0.9905	0.9255	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:06	SEYMQAAL	0.9898	0.9196	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:03	SEYMQAAL	0.9885	0.9009	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:11	SEYMQAAL	0.9869	0.8288	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B41:03	SEYMQAAL	0.9652	0.5243	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:02	SEYMQAAL	0.8688	0.9387	9	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:04	SEYMQQAA	0.8634	0.7877	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:05	SEYMQQAA	0.8634	0.7877	8	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:04	SEYMQQAAL	0.9989	0.7437	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C03:04	YMQAALKQL	0.9956	0.9834	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C03:03	YMQAALKQL	0.9956	0.9834	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B44:07	SEYMQQAAL	0.99	0.938	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B44:13	SEYMQQAAL	0.99	0.938	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B44:26	SEYMQQAAL	0.99	0.938	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:03	YMQAALKQL	0.9897	0.6256	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:24	MQQAALKQL	0.9891	0.9388	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C03:05	YMQAALKQL	0.9878	0.923	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C03:67	YMQAALKQL	0.9815	0.9758	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:06	YMQAALKQL	0.9731	0.5851	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:14	YMQAALKQL	0.9722	0.5655	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C01:03	YMQAALKQL	0.9695	0.9674	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:02	MQQAALKQL	0.9493	0.9802	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:04	SEYMQQAAL	0.9434	0.9278	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:07	SEYMQQAAL	0.9367	0.8788	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:73	MQQAALKQL	0.9321	0.98	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C01:02	YMQAALKQL	0.9274	0.9632	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:73	YMQAALKQL	0.9177	0.9624	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:05	SEYMQQAAL	0.914	0.9232	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C06:06	YMQAALKQL	0.9132	0.9902	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:08	SEYMQQAAL	0.9123	0.9623	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:68	MQQAALKQL	0.9053	0.7993	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:12	MQQAALKQL	0.9027	0.869	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:53	MQQAALKQL	0.8821	0.8912	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:30	YMQAALKQL	0.8796	0.9413	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:12	MQQAALKQL	0.8788	0.5513	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:30	MQQAALKQL	0.875	0.9685	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:03	ELSEYMQQA	0.8742	0.7022	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:06	SEYMQQAAL	0.8714	0.9426	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:03	SEYMQQAAL	0.8612	0.9165	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B18:11	SEYMQQAAL	0.8394	0.8625	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:54	MQQAALKQL	0.838	0.8893	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C07:04	YMQAALKQL	0.8124	0.9555	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B41:03	SEYMQQAAL	0.7867	0.5401	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:49	MQQAALKQL	0.781	0.5094	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:11	SEYMQQAAL	0.7514	0.719	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B40:21	MQQAALKQL	0.7314	0.6914	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B48:02	MQQAALKQL	0.7117	0.9607	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:31	SEYMQQAAL	0.6926	0.9384	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B39:02	SEYMQQAAL	0.676	0.9483	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-C17:01	YMQAALKQL	0.6089	0.9329	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:05	FELSEYMQA	0.5703	0.7583	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:04	FELSEYMQA	0.5703	0.7583	6	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B35:28	MQQAALKQL	0.4873	0.9639	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B48:02	SEYMQQAAL	0.4218	0.9299	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:05	SEYMQQAAL	0.3851	0.759	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:04	SEYMQQAAL	0.3851	0.759	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:54	SEYMQQAAL	0.3533	0.8427	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:09	SEYMQQAAL	0.3473	0.5426	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:68	SEYMQQAAL	0.3438	0.657	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B07:13	YMQAALKQL	0.334	0.7895	11	20
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B15:53	SEYMQQAAL	0.3029	0.8406	8	17
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:04	FELSEYMQAA	0.8862	0.7925	6	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:05	FELSEYMQAA	0.8862	0.7925	6	16
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:04	FELSEYMQQA	0.8189	0.7803	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-B50:05	FELSEYMQQA	0.8189	0.7803	5	15
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	HLA-A02:03	FELSEYMQQA	0.6568	0.7264	5	15

Top

Potential FusionNeoAntigen Information of CDC27-C17orf53 in HLA II

CDC27-C17orf53_45219219_42231924.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-0812	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-0812	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-0831	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-0831	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1113	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1113	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1117	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1117	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1134	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1134	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1141	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1141	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1150	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1150	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1152	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1152	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1156	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1156	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1157	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1157	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1183	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1183	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1188	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1188	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1189	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1189	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1192	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1192	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1204	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1204	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1208	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1208	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1209	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1209	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1220	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1220	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1304	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1304	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1309	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1309	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-13100	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-13100	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1331	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1331	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1332	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1332	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1343	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1343	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1344	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1344	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1346	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1346	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1348	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1348	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1354	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1354	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1358	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1358	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1375	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1375	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1376	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1376	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1377	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1377	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1381	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1381	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1393	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1393	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1401	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1401	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1404	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1404	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1405	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1405	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1406	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1406	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1407	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1407	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1408	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1408	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1411	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1411	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1412	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1412	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1416	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1416	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1417	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1417	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1418	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1418	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1420	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1420	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1421	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1421	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1423	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1423	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1426	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1426	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1428	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1428	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1429	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1429	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1431	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1431	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1432	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1432	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1433	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1433	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1434	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1434	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1435	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1435	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1437	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1437	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1438	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1438	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1439	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1439	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1443	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1443	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1445	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1445	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1449	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1449	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1450	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1450	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1452	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1452	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1454	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1454	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1455	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1455	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1456	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1456	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1458	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1458	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1459	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1459	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1460	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1460	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1461	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1461	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1462	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1462	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1464	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1464	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1465	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1465	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1468	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1468	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1469	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1469	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1470	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1470	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1471	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1471	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1472	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1472	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1473	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1473	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1474	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1474	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1475	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1475	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1478	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1478	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1480	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1480	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1481	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1481	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1482	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1482	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1483	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1483	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1486	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1486	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1487	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1487	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1488	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1488	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1490	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1490	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1491	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1491	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1495	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1495	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1496	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1496	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1497	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1497	MQQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1499	YMQAALKQLPRNKVP	11	26
CDC27-C17orf53	chr17	45219219	chr17	42231924	1645	DRB1-1499	MQQAALKQLPRNKVP	11	26

Top

Fusion breakpoint peptide structures of CDC27-C17orf53

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1924	ELSEYMQQAALKQL	CDC27	C17orf53	chr17	45219219	chr17	42231924	1645

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2341	FELSEYMQAALKQL	CDC27	C17orf53	chr17	45219219	chr17	42231924	1645

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CDC27-C17orf53

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B52:01	3W39	1924	ELSEYMQQAALKQL	-7.90165	-7.90165
HLA-B44:05	3DX8	1924	ELSEYMQQAALKQL	-5.81679	-5.81679
HLA-B14:02	3BVN	2341	FELSEYMQAALKQL	-7.9962	-8.1096
HLA-B14:02	3BVN	2341	FELSEYMQAALKQL	-5.70842	-6.74372
HLA-B52:01	3W39	2341	FELSEYMQAALKQL	-6.83737	-6.95077
HLA-B52:01	3W39	2341	FELSEYMQAALKQL	-4.4836	-5.5189
HLA-A11:01	4UQ2	2341	FELSEYMQAALKQL	-10.0067	-10.1201
HLA-A11:01	4UQ2	2341	FELSEYMQAALKQL	-9.03915	-10.0745
HLA-A24:02	5HGA	2341	FELSEYMQAALKQL	-6.56204	-6.67544
HLA-A24:02	5HGA	2341	FELSEYMQAALKQL	-5.42271	-6.45801
HLA-B44:05	3DX8	2341	FELSEYMQAALKQL	-7.85648	-8.89178
HLA-B44:05	3DX8	2341	FELSEYMQAALKQL	-5.3978	-5.5112
HLA-A02:01	6TDR	2341	FELSEYMQAALKQL	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CDC27-C17orf53

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
CDC27-C17orf53	chr17	45219219	chr17	42231924	11	20	MQQAALKQL	ATGCAACAGGCAGCCCTGAAGCAGCTT
CDC27-C17orf53	chr17	45219219	chr17	42231924	11	20	YMQAALKQL	ATGCAAGCAGCCCTGAAGCAGCTTCCT
CDC27-C17orf53	chr17	45219219	chr17	42231924	12	20	MQAALKQL	CAAGCAGCCCTGAAGCAGCTTCCT
CDC27-C17orf53	chr17	45219219	chr17	42231924	4	15	AYFELSEYMQA	TATTTTGAACTTTCAGAGTACATGCAAGCAGCC
CDC27-C17orf53	chr17	45219219	chr17	42231924	5	15	FELSEYMQQA	TTTGAACTTTCAGAGTACATGCAACAGGCA
CDC27-C17orf53	chr17	45219219	chr17	42231924	6	15	ELSEYMQQA	GAACTTTCAGAGTACATGCAACAGGCA
CDC27-C17orf53	chr17	45219219	chr17	42231924	6	15	FELSEYMQA	GAACTTTCAGAGTACATGCAAGCAGCC
CDC27-C17orf53	chr17	45219219	chr17	42231924	6	16	FELSEYMQAA	GAACTTTCAGAGTACATGCAAGCAGCCCTG
CDC27-C17orf53	chr17	45219219	chr17	42231924	8	16	SEYMQQAA	TCAGAGTACATGCAACAGGCAGCC
CDC27-C17orf53	chr17	45219219	chr17	42231924	8	17	SEYMQQAAL	TCAGAGTACATGCAACAGGCAGCCCTG
CDC27-C17orf53	chr17	45219219	chr17	42231924	9	17	SEYMQAAL	GAGTACATGCAAGCAGCCCTGAAG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
CDC27-C17orf53	chr17	45219219	chr17	42231924	11	26	MQQAALKQLPRNKVP	ATGCAACAGGCAGCCCTGAAGCAGCTTCCTAGGAACAAGGTCCCC
CDC27-C17orf53	chr17	45219219	chr17	42231924	11	26	YMQAALKQLPRNKVP	ATGCAAGCAGCCCTGAAGCAGCTTCCTAGGAACAAGGTCCCCAAC

Top

Information of the samples that have these potential fusion neoantigens of CDC27-C17orf53

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
CESC	CDC27-C17orf53	chr17	45219219	ENST00000066544	chr17	42231924	ENST00000245382	TCGA-4J-AA1J-01A
CESC	CDC27-C17orf53	chr17	45219219	ENST00000066544	chr17	42231924	ENST00000319977	TCGA-4J-AA1J-01A

Top

Potential target of CAR-T therapy development for CDC27-C17orf53

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to CDC27-C17orf53

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to CDC27-C17orf53

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)